The Vanguard Group has filed an amendment to its Schedule 13G, indicating a change in its holdings of Novavax Inc common stock. As of September 30, 2024, The Vanguard Group reported beneficial ownership of 15,430,034 shares of Novavax, representing 9.63% of the company's class of common stock. The filing, made under Rule 13d-1(b) of the Securities Exchange Act of 1934, shows that The Vanguard Group has shared voting power over 224,741 shares and sole dispositive power over 15,072,218 shares, with an additional shared dispositive power over 357,816 shares. This amendment reflects The Vanguard Group's position as a significant investor in Novavax, with the reported shares being held on behalf of its clients, including registered investment companies and other managed accounts.

The Vanguard Group has filed an amendment to its Schedule 13G, indicating a change in its holdings of Novavax Inc common stock. As of September 30, 2024, The Vanguard Group reported beneficial ownership of 15,430,034 shares of Novavax, representing 9.63% of the company's class of common stock. The filing, made under Rule 13d-1(b) of the Securities Exchange Act of 1934, shows that The Vanguard Group has shared voting power over 224,741 shares and sole dispositive power over 15,072,218 shares, with an additional shared dispositive power over 357,816 shares. This amendment reflects The Vanguard Group's position as a significant investor in Novavax, with the reported shares being held on behalf of its clients, including registered investment companies and other managed accounts.